Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis

NANot yet recruitingINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Anal CancerSquamous Intraepithelial LesionsHSIL, High Grade Squamous Intraepithelial LesionsLSIL, Low-Grade Squamous Intraepithelial LesionsHPVSquamous Cell Carcinoma
Interventions
DIAGNOSTIC_TEST

Anal smear

"The intervention in this study involves the anal smear collection using the FLOQSwab® (COPAN, pouch type 502CS01). The swab is inserted 3-5 cm into the anal canal, reaching the transitional zone, the pressed against the canal wall and withdrawn in a spiral motion over approximately 20 seconds. After collection, the swab is immediately placed into a ThinPrep vial containing 20 ml of PreservCyt® and rinsed vigorously.~The procedure is performed by a physician or trained study team member and is designed to be quick, minimally invasive, and comfortable for participants. The FLOQSwab®'s patient-friendly design reduces irritation and false-positive results in comparison to earlier methods.~Samples collected in the ThinPrep PreservCyt® solution should be stored at room temperature and transferred to AML within a maximum of six weeks"

BEHAVIORAL

Self-administered questionnaire

"It includes questions related to:~Socio-demographic characteristics Health-related issues Past HPV vaccination (indication? age at vaccination?) History of condylomata and/or other STIs Drug use, tobacco use, alcohol use Anal symptoms: discomfort, itch, pain, nodules, blood loss/discharge, constipation Sexual behavior Insertive/receptive intercourse, chemsex, number of sex partners (stable, occasional, anonymous), condom use."

BEHAVIORAL

EQ-5D-5L questionnaire

"This questionnaire will be used after a negative HRA or during the communication of the results (per telephone) and during the treatment if indicated. This questionnaire assesses the impact of health conditions and treatments on person's quality of life. We will use an adapted version of the EQ-5D-5L. This modified version includes additional questions tailored to assess specific domains highlighted in the A-HRSI.~The additional items cover:~* Physical Symptoms: Question on anal symptoms such as pain, discharge, and burning sensations.~* Impact on Physical Functioning: Question on how these symptoms affect daily activities, including work, sitting, and social interactions.~* Impact on Psychological Functioning: Question on psychological and sexual well-being, including enjoyment and desire for sex, as well as challenges with intimacy."

DIAGNOSTIC_TEST

High Resolution Anoscopy (HRA)

"HRA will be conducted using advanced tools, such as the Zeiss Extaro at UZ Brussel.~HRA will be conducted at participating centers with expertise in the technique, including UZ Brussel, UZ Gent, UZ Leuven, UZ Antwerpen, CHU St Pierre, AZ Sint-Jan Brugge, and Citadelle Liège. However, all biopsy specimens will be sent to AML Lab for analysis and stored in the biobank (BB190002).~In certain centers, HRA is performed using high-resolution scopes."

Trial Locations (7)

1000

CHU Saint-Pierre, Brussels

1200

Cliniques universitaires Saint-Luc - UCLouvain, Brussels

3000

UZ Leuven, Leuven

6042

CHU Charleroi - Chimay, Lodelinsart

8000

AZ Sint Jan, Bruges

9000

UZ Gent, Ghent

Unknown

UZ Brussel, Brussels

All Listed Sponsors
collaborator

A.M.L.

UNKNOWN

lead

Universitair Ziekenhuis Brussel

OTHER